Medy-Tox Inc. (086900.KQ)
KRW 124900.0
(-2.42%)
KRW 124900.0
(-2.42%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 128.16 Billion KRW | 3.24% |
| 2022 | 124.13 Billion KRW | 21.16% |
| 2021 | 102.45 Billion KRW | 43.73% |
| 2020 | 71.28 Billion KRW | -46.69% |
| 2019 | 133.71 Billion KRW | -9.98% |
| 2018 | 148.53 Billion KRW | 3.1% |
| 2017 | 144.07 Billion KRW | 34.89% |
| 2016 | 106.81 Billion KRW | 47.69% |
| 2015 | 72.32 Billion KRW | 5.17% |
| 2014 | 68.76 Billion KRW | 101.82% |
| 2013 | 34.07 Billion KRW | 3.93% |
| 2012 | 32.78 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 32.33 Billion KRW | -15.86% |
| 2024 Q2 | 40.59 Billion KRW | 27.9% |
| 2023 Q2 | 31.94 Billion KRW | 35.39% |
| 2023 FY | 128.16 Billion KRW | 3.24% |
| 2023 Q4 | 38.43 Billion KRW | 4.54% |
| 2023 Q1 | 23.59 Billion KRW | -32.05% |
| 2023 Q3 | 36.76 Billion KRW | 15.08% |
| 2022 Q3 | 34.04 Billion KRW | 9.93% |
| 2022 FY | 124.13 Billion KRW | 21.16% |
| 2022 Q4 | 34.72 Billion KRW | 2.0% |
| 2022 Q2 | 30.96 Billion KRW | 30.97% |
| 2022 Q1 | 23.64 Billion KRW | 38.11% |
| 2021 FY | 102.45 Billion KRW | 43.73% |
| 2021 Q1 | 15.5 Billion KRW | -23.15% |
| 2021 Q2 | 19.55 Billion KRW | 26.11% |
| 2021 Q3 | 50.27 Billion KRW | 157.07% |
| 2021 Q4 | 17.11 Billion KRW | -65.95% |
| 2020 Q3 | 12.19 Billion KRW | -44.53% |
| 2020 Q4 | 20.17 Billion KRW | 65.42% |
| 2020 FY | 71.28 Billion KRW | -46.69% |
| 2020 Q2 | 21.99 Billion KRW | 12.6% |
| 2020 Q1 | 19.53 Billion KRW | -46.27% |
| 2019 FY | 133.71 Billion KRW | -9.98% |
| 2019 Q1 | 31.51 Billion KRW | 1.38% |
| 2019 Q2 | 37.55 Billion KRW | 19.16% |
| 2019 Q4 | 36.35 Billion KRW | 19.42% |
| 2019 Q3 | 30.43 Billion KRW | -18.94% |
| 2018 Q4 | 31.08 Billion KRW | -11.79% |
| 2018 FY | 148.53 Billion KRW | 3.1% |
| 2018 Q3 | 35.23 Billion KRW | -9.89% |
| 2018 Q2 | 39.1 Billion KRW | -13.68% |
| 2018 Q1 | 45.3 Billion KRW | 9.29% |
| 2017 Q3 | 32.51 Billion KRW | -16.94% |
| 2017 Q1 | 32.85 Billion KRW | 3.63% |
| 2017 Q2 | 39.14 Billion KRW | 19.17% |
| 2017 Q4 | 41.45 Billion KRW | 27.47% |
| 2017 FY | 144.07 Billion KRW | 34.89% |
| 2016 Q4 | 31.7 Billion KRW | 17.66% |
| 2016 Q3 | 26.94 Billion KRW | 2.29% |
| 2016 Q2 | 26.34 Billion KRW | 10.55% |
| 2016 Q1 | 23.82 Billion KRW | 14.23% |
| 2016 FY | 106.81 Billion KRW | 47.69% |
| 2015 Q2 | 18.41 Billion KRW | 14.48% |
| 2015 Q1 | 16.08 Billion KRW | 27.2% |
| 2015 Q4 | 20.85 Billion KRW | 11.76% |
| 2015 Q3 | 18.66 Billion KRW | 1.34% |
| 2015 FY | 72.32 Billion KRW | 5.17% |
| 2014 Q1 | 11.73 Billion KRW | 52.88% |
| 2014 Q4 | 12.64 Billion KRW | -58.09% |
| 2014 Q2 | 14.2 Billion KRW | 21.06% |
| 2014 Q3 | 30.17 Billion KRW | 112.42% |
| 2014 FY | 68.76 Billion KRW | 101.82% |
| 2013 Q2 | 9.74 Billion KRW | 23.46% |
| 2013 Q4 | 7.67 Billion KRW | -12.29% |
| 2013 FY | 34.07 Billion KRW | 3.93% |
| 2013 Q1 | 7.89 Billion KRW | -19.72% |
| 2013 Q3 | 8.75 Billion KRW | -10.24% |
| 2012 FY | 32.78 Billion KRW | 0.0% |
| 2012 Q4 | 9.83 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| HLB Co., Ltd. | -6.01 Billion KRW | 2231.599% |
| iNtRON Biotechnology, Inc. | 4.56 Billion KRW | -2710.032% |
| BINEX Co., Ltd. | 56.65 Billion KRW | -126.213% |
| Bioneer Corporation | 199.25 Billion KRW | 35.679% |
| Anterogen.Co.,Ltd. | 2.21 Billion KRW | -5690.171% |
| MEDIPOST Co., Ltd. | 40.18 Billion KRW | -218.937% |
| CrystalGenomics, Inc. | 1.45 Billion KRW | -8696.259% |
| Helixmith Co., Ltd | 2.12 Billion KRW | -5940.102% |
| Chabiotech Co.,Ltd. | 255.19 Billion KRW | 49.778% |
| Peptron, Inc. | 1.14 Billion KRW | -11136.57% |
| Amicogen, Inc. | 51.51 Billion KRW | -148.796% |
| Genexine, Inc. | 387.48 Million KRW | -32975.35% |
| HLB Therapeutics Co.,Ltd. | 6.69 Billion KRW | -1814.507% |
| LegoChem Biosciences, Inc. | 17.79 Billion KRW | -620.12% |
| ALTEOGEN Inc. | 31.19 Billion KRW | -310.795% |
| PharmaResearch Co., Ltd. | 182.25 Billion KRW | 29.68% |
| SillaJen, Inc. | 1.45 Billion KRW | -8697.844% |
| JETEMA, Co., Ltd. | 26.58 Billion KRW | -382.139% |
| OliX Pharmaceuticals,Inc | 14.42 Billion KRW | -788.636% |
| Genomictree Inc. | -1.03 Billion KRW | 12439.953% |
| MedPacto, Inc. | -1.83 Billion KRW | 7093.201% |
| D&D Pharmatech | 18.67 Billion KRW | -586.201% |
| EASY BIO,Inc. | 50.88 Billion KRW | -151.861% |
| GI Innovation, Inc. | 1.98 Billion KRW | -6342.167% |